Skip to content

Journal · Dermatology · Updated 21 November 2026

Dermatology and Therapy

Read Dermatology and Therapy articles on DeepDyve. No university library needed.

Dermatology and Therapy has published since 2011 and covers the treatment of skin disease, from acne and atopic dermatitis to new drugs, real-world studies and skin aging. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Dermatology and Therapy
Journal cover

Dermatology and Therapy at a glance

Full title
Dermatology and Therapy
Abbreviation (NLM)
Dermatol Ther (Heidelb)
Publisher
Springer Nature
Print ISSN
2193-8210
Online ISSN (eISSN)
2190-9172
First published
2011
Access model
Open access since 2011

Ways to access Dermatology and Therapy

All of the articles Dermatology and Therapy published from January 1 to November 19, 2026 are open access and free to read. For older articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 100% of Dermatology and Therapy articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Dermatology and Therapy. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Dermatology and Therapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Dermatology and Therapy’s 2025 Journal Impact Factor is 4.6, and its 5-year Impact Factor is 4.5.

4.6

Journal Impact Factor (2025)

4.5

5-year Impact Factor (2025)

4 days

Median time to first decision

2.3M

Downloads (2025)

Source: journal metrics on the Dermatology and Therapy homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Dermatology and Therapy research worth reading

Published January to April 2026. Summaries describe what the authors report.

  1. Open accessAcne · Isotretinoin

    Expert Consensus on the Rational Approach to Isotretinoin Usage for Effective Management of Acne: ERAISE ACNE Recommendations

    In a Delphi consensus of 20 dermatology experts, the authors set out recommendations for oral isotretinoin in acne in Indian practice, favoring early use for severe or scarring acne and tailored dosing, with no consensus on cumulative dosing or lab testing frequency.

    Kandhari et al. · Dermatology and Therapy, published online March 31, 2026 · DOI 10.1007/s13555-026-01681-6

  2. Open accessSkin aging · Epigenetics

    Epigenetic Skin Aging and Its Reversal to Improve Skin Longevity across Ethnicities and Phototypes Using a Dihydromyricetin-Containing Serum: Results from a Prospective, Single-Cohort Study

    Profiling skin DNA methylation in donors of several ethnicities, the authors report that age-related methylation patterns are shared across populations, and that in 60 participants an 8-week dihydromyricetin serum lowered epidermal methylation age and reduced skin roughness.

    Qi et al. · Dermatology and Therapy, published online April 25, 2026 · DOI 10.1007/s13555-026-01764-4

  3. Open accessAcne · Microbiome

    Prebiotics, Probiotics, and Postbiotics for Acne Vulgaris: A Systematic Review

    Reviewing 33 studies of 2112 patients, the authors report that prebiotic, probiotic and postbiotic treatments for acne were safe, with no serious adverse events, and were associated with clinically meaningful lesion reductions, with probiotics having the strongest evidence.

    Warp et al. · Dermatology and Therapy, published online February 17, 2026 · DOI 10.1007/s13555-026-01659-4

  4. Open accessAtopic dermatitis · JAK inhibitors

    Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib

    In 57 Korean patients with moderate-to-severe atopic dermatitis who completed 16 weeks of abrocitinib, the authors report that 72.2% reached EASI-75, with acne the most common adverse event and no discontinuations due to adverse events.

    Gwag et al. · Dermatology and Therapy, published online February 23, 2026 · DOI 10.1007/s13555-026-01679-0

  5. Open accessAtopic dermatitis · Biologics

    Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study

    In the open-label ADapt trial of 86 patients with moderate-to-severe atopic dermatitis who had stopped dupilumab, the authors report that 57.4% reached EASI 75 at week 16 on lebrikizumab, with mostly mild or moderate adverse events.

    Silverberg et al. · Dermatology and Therapy, published online January 19, 2026 · DOI 10.1007/s13555-025-01644-3

See every Dermatology and Therapy article on DeepDyve

Questions about Dermatology and Therapy

How can I read Dermatology and Therapy articles without a subscription?

100% of Dermatology and Therapy articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Dermatology and Therapy articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Dermatology and Therapy?

Dermatology and Therapy’s NLM (PubMed) abbreviation is Dermatol Ther (Heidelb).

What is the ISSN of Dermatology and Therapy?

The print ISSN is 2193-8210 and the online ISSN is 2190-9172.

What is the impact factor of Dermatology and Therapy?

Dermatology and Therapy’s Journal Impact Factor is 4.6 (2025), and its 5-year Impact Factor is 4.5, according to Springer Nature’s published metrics.

Is Dermatology and Therapy open access?

Yes. Dermatology and Therapy has published open access since 2011: 327 of the 327 articles it published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref.

Dermatology and Therapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Dermatology and Therapy today

One month free, then less than $2 a day. Dermatology and Therapy, plus millions of articles from thousands of journals.

Start free month

Like this: